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CaBPs are a family of Ca2þ-binding proteins related to calmodulin and are localized in the brain and sensory organs, including the retina
and cochlea. Although their physiological roles are not yet fully elucidated, CaBPs modulate Ca2þ signaling through effectors such as
voltage-gated Cav Ca
2þ channels. In this study, we identified a splice-site mutation (c.637þ1G>T) in Ca2þ-binding protein 2 (CABP2)
in three consanguineous Iranian families affected by moderate-to-severe hearing loss. This mutation, most likely a founder mutation,
probably leads to skipping of exon 6 and premature truncation of the protein (p.Phe164Serfs*4). Compared with wild-type CaBP2,
the truncated CaBP2 showed altered Ca2þ binding in isothermal titration calorimetry and less potent regulation of Cav1.3 Ca
2þ chan-
nels. We show that genetic defects in CABP2 cause moderate-to-severe sensorineural hearing impairment. The mutation might cause
a hypofunctional CaBP2 defective in Ca2þ sensing and effector regulation in the inner ear.Introduction
Hearing loss is a common sensory disorder that can signif-
icantly impact quality of life. The estimated incidence of
congenital hearing loss in developed countries is 1 in
650–1,000, and the majority of cases are attributable to
genetic factors.1 Genetic hearing loss can be part of a syn-
drome or the only detectable disease manifestation (non-
syndromic). Autosomal-recessive nonsyndromic hearing
loss (arNSHL) is the most common type of inherited
hearing loss and is genetically heterogeneous; 61 genes
and >100 loci have been reported (Hereditary Hearing
LossHomepage). The fact that genetic hearing loss is excep-
tionally heterogeneous can be explained by the complexity
of the auditory system, which involves coordination of
multiple processes involving different parts of the ear and
nervous system. A defect in any part of this complex chain
of events can lead to hearing impairment or deafness.
Most families segregating arNSHL typically have a prelin-
gual, bilateral, severe-to-profound hearing loss. An excep-
tion is found with mutations in TECTA (MIM 602574)
and STRC (MIM 606440); these mutations cause prelingual
moderate-to-severe hearing loss that is usually most
pronounced in the mid-frequency range.2–4 Recently, we
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a similar moderate-to-severe hearing-loss phenotype.5
This is the third arNSHL-associated locus associated with
a milder phenotype.
CaBP2 is a member of a subfamily of Ca2þ binding
proteins with high similarity to calmodulin (CALM1).6
Like calmodulin, CaBP family members interact with and
regulate effectors such as voltage-gated Cav channels in a
Ca2þ-dependent manner.7,8 In the cochlea, Ca2þ influx
through Cav1.3 (L-type) Ca
2þ channels into hair cells
triggers synaptic transmission to spiral ganglion neurons
that convey the auditory information to the brain.9,10
Ca2þ-binding proteins (CABPs) localized in hair cells
might modulate presynaptic Ca2þ influx, e.g., by antago-
nizing calmodulin-mediated Ca2þ-dependent inactivation
(CDI) of Cav1.3 channels.
11,12 Here, we report that a muta-
tion in CABP2 (MIM 607314) is the cause of DFNB93
moderate-to-severe hearing loss and reveal a role for
CaBP2 in the mammalian auditory system.
Material and Methods
Clinical Investigation
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Figure 1. Pedigrees
(A–C) Pedigrees and segregation of the c.637þ1G>T (p.Phe164Serfs*4) mutation in Iranian families Sh11 (A), Sh10 (B), and He (C).
(D) Sequencing results of the c.637þ1G>T mutation. The affected individual sequenced with next-generation sequencing is indicated
with an arrow. Nomenclature was based on NM_016366.2 and NP_057450.2.with air conduction at 250, 500, 1,000, 2,000, 4,000 and 8,000 Hz,
and bone conduction was performed at 250, 500, 1,000, 2,000,
and 4,000 Hz. In addition, transient-evoked otoacoustic emissions
(TEOAEs) were recorded in all affected individuals and click-
evoked broadband (100–3,000 Hz) auditory brainstem response
(ABR)measurements were done on a subset of affected individuals.
All affected members underwent comprehensive ophthalmolog-
ical examinations, including a visual acuity test, a color vision
test, cover test, retinoscopy, autorefractors, slit-lamp examination,
pupil dilation, and a visual field test. To investigate cardiovascular
problems, we recorded electrocardiograms and echocardiographs
on most of the affected individuals.
All Iranian families and 100 Iranian controls were ascertained by
the Cellular andMolecular Research Center, Shahrekord, Iran. The
three families affected by mutations in CABP2 are of Iranian
ethnicity. Families Sh10 and Sh11 live in the Fars province in
the south of Iran, and the He family is from the Chaharmahal
va Bakhtiari province in the southwest of Iran. All medical exam-
inations of the Sh10, Sh11, and He families were performed in
a local clinical center.
An additional 24 unrelated Belgian and Dutch individuals who
show a specific moderate-to-severe hearing-loss profile were col-
lected through the Centre of Medical Genetics, Antwerp and
Radboud University Nijmegen Medical Centre.
Fourteen unrelated families affected by Usher syndrome were
collected through the Radboud University Medical Centre. Five
families were diagnosed with Usher syndrome type I (USH1
[MIM 276900]), five families were diagnosed with Usher syndrome
type II (USH2 [MIM 276901]), and four families were diagnosed
with atypical Usher syndrome. Per family, DNA was available
from the parents, one to three affected individuals, and one toThe Americthree unaffected individuals. These families could so far not be
explained by two mutated alleles of the nine known genes in
which mutations cause Usher syndrome; these genes are MYO7A
(MIM 276903), USH1C (MIM 605242), CDH23 (MIM 605516),
PCDH15 (MIM 605514), USH1G (MIM 607696), USH2A (MIM
608400), GPR98 (MIM 602851), DFNB31 (MIM 607928), and
CLRN1 (MIM 606397).
This study was carried out according to the guidelines of the
ethical committees of the University of Antwerp and Shahrekord
University of Medical Sciences. Informed consent was obtained
from all individuals.Target Enrichment and Next-Generation Sequencing
Wedeveloped a customSureSelect DNAcapture array (1M) (Agilent
Technologies, Santa Clara, USA) that contains all gene exons and
noncoding RNAs in the complete 9.6 Mb DFNB93 region. Gene
exons and noncoding RNA coordinates were selected on the
basis of the Ensembl genome database (hg19/GRCh37 draft).5
In addition, we added 1,000 bp to the 50 UTR of each gene and
50 bp to the 50 end and 20 bp to the 30 end of each exon to
include the promoter region and to detect possible splice-site
mutations. We then filtered the final selected region (1.3 Mb)
for repeats (UCSC RepeatMasker) to exclude the development
of probes that capture nonspecific regions in the genome. The
custom DNA capture array was designed with a 203 probe tiling.
DNA from affected member V:14 of the DFNB93-affected family
(Sh10; Figure 1) was fragmented with a Covaris S220 instrument
(Covaris, Woburn, USA). Subsequently, the sample was prepared
for sequencing according to the SureSelect DNA Capture Array
protocol (Agilent Technologies, Santa Clara, USA). In short,an Journal of Human Genetics 91, 636–645, October 5, 2012 637
universal adaptor nucleotides were ligated, and the library was
amplified before hybridization to the array (65C for 65 hr).
Hybridized molecules were eluted, amplified, and quantified
with quantitative PCR (qPCR) and diluted to a final concentration
of 10 nM. Enriched DNA fragments were then sequenced on an Il-
lumina Genome Analyzer, GAIIx (Illumina, San Diego, USA) with
the use of 13 72 bp reads.
Data Analysis
NextGENe (SoftGenetics, State College, USA), a workbench for
computational analysis of genomic data, was used for quality
control, data manipulation, alignment to the human genome,
and detection of indels and variants. Because sequencing revealed
a great number of homozygous variants, we next used the program
ANNOVAR13 to perform a stepwise filtering approach to screen the
identified variants in order to select those likely to be implicated in
the disorder. First, variants present in the 1000 Genome Project
Full Project Phase 1 (November 2010 release) or in dbSNP131
were excluded. Second, variants were annotated and screened for
nonsynonymous variants, nonsense mutations, frameshift muta-
tions, splice-site mutations, and coding indels.
Sanger DNA Sequencing
Primers surrounding possibly damaging variants identified by
next-generation sequencing and surrounding all exons of CABP2
were designed with primer3 software.14 PCR was carried out under
standard conditions, and direct sequencing of the PCR product
was performed on an ABI 3130xl sequencer (Applied Biosystems,
Foster City, USA).
Genotyping
Linkage to the DFNB93 region and refinement of the region
were done by genotyping microsatellite markers and SNPs. Infor-
mation for microsatellite markers was taken from the NCBI STS
database. Markers CABP2M4, CABP2M5, and CABP2M8 are not
in this database and were developed on the basis of the human
genome sequence (NCBI build 37.2) (primers are available upon
request). In short, PCR was carried out under standard conditions.
PCR products were fluorescently labeled, and capillary electropho-
resis and pattern visualization were performed with an ABI 3130xl
automatic DNA sequencer (Applied Biosystems, Foster City, USA).
SNPs were genotyped by direct sequencing of the PCR product as
described in the previous section.
Exon Trapping
Using genomic DNA from an affected and control individual, we
used PCR to amplify a fragment containing 105 bp of CABP2
intron 5, 148 bp of CABP2 exon 6, and 622 bp of CABP2 intron 6
(with wild-type [WT] and mutant [MT] 50 donor sites), and we
cloned it into the pSPL3 exon trapping vector (Life technologies,
Carlsbad, USA) by using BamHI and EcoRI restriction enzymes
(Fermentas, St. Leon-Rot, Germany). COS-7 cells were seeded in
60 mm dishes and transfected with 2 mg plasmid DNA (WT, MT,
and empty pSPL3) by the use of FuGENE 6 transfection reagent
(Roche, Basel, Switzerland). All transfections were performed in
duplicates. Total RNA was extracted 24 hr after transfection with
the use of Trizol reagent (Invitrogen, Carlsbad, USA), RNA was
DNase treated with the DNA-free kit (Ambion, Austin, USA), and
cDNA was made by means of reverse transcriptase with the SA2
primers and Superscript III Reverse Transcriptase (Invitrogen,
Carlsbad, USA). Subsequently, PCR was used for amplifying638 The American Journal of Human Genetics 91, 636–645, OctobercDNA with pSPL3 primers SD6 and SA2 and was followed by
a nested PCR reaction with dUSD2 and dUSA4 primers (Life tech-
nologies, Carlsbad, USA). Products were visualized with agarose-
gel electrophoresis. Bands were cut out and purified by the QiaEX
gel extraction kit II (QIAGEN, Hilden, Germany) before se-
quencing. Sequencing was performed on an ABI 3130xl sequencer
(Applied Biosystems, Foster City, USA). The results were confirmed
by repeated independent PCR and sequencing reactions.CaBP2 Constructs, Purification, and Ca2þ-Binding
Assays
Before amplifying CaBP2 from the cDNA clone IRAKp961K1413Q
(ImaGenes GmbH, Berlin, Germany) with oligonucleotides
CABP2O1 and CABP2O2, we removed a 4 nt insertion after exon
2 of the original cDNA to obtain the sequence as reported in
RefSeq NM_016366.2 by means of overlap PCR. For this, two frag-
ments of CaBP2 were amplified (primer: fwd1, rev1; fwd2, rev2)
and fused to one construct by overlap PCR. Overlap PCR was
also used for introducing a premature stop codon (p.Phe164*), re-
sulting in a construct comparable to the result of exon skipping
evoked by the CABP2 c.637þ1G>T mutation (primers: fwd1,
rev2; p.Phe164*, rev3, fwd3). All CaBP2 constructs were subcloned
into a pET28a vector (EMD Biosciences, San Diego, CA) with
restriction sites BamHI and NotI such that an N-terminal His6-
tag was fused to all CaBP2 constructs. All constructs were verified
by DNA sequencing.
Protein purification was performed as described earlier.15 In
brief, the E. coli strain Rosetta 2 (DE3) (Agilent Technologies)
was transformed with pET28a containing cDNA for His6-CaBP2-
wt or His6-CaBP2-p.Phe164*, and 100 ml of bacterial overnight
culture was inoculated in 5 l of 2YT medium (BD Biosciences,
Franklin Lakes, NJ) and grown at 30C. Overexpression was
induced by the addition of 1 mM isopropyl b-D-1-thiogalactopyr-
anoside at an optical density (at 600 nm) of 0.6 and incubation at
16C for 15–20 hr. Cells were harvested by centrifugation, resus-
pended, and opened up with a Branson 250 sonicator (Branson,
Danbury, CT). After centrifugation at 21,280 g, the His6-tagged
proteins were affinity purified from the supernatant with a HisTrap
FF crude column (GEHealthcare,Munich, Germany). The proteins
were eluted from the column, and the His6-tag was cleaved by the
incubation of the protein solution with 1 U thrombin per 1 ml
protein solution overnight at 4C. Next, we added 5 mM of
EDTA for chelation of Ca2þ and then reduced the volume of the
protein solution in a Vivaspin 20 (10,000 MWCO) concentrator
(Sartorius Stedim Biotech, Go¨ttingen, Germany). This protein
fraction was loaded on a gel-filtration column (Superdex 200
10/300, GE Healthcare) and run at 0.5 ml/min in buffer (pH 7.4)
pretreated with Chelex100 (Bio-Rad, Munich, Germany). Only
the fractions corresponding to the monomers of CaBP2-wt or
CaBP2-p.Phe164* were collected for Ca2þ-binding assays, and
the volume was further reduced in a Vivaspin 20 concentrator
(Sartorius Stedim Biotech). Both proteins were readily purified in
the absence and presence of Ca2þ. However, Ca2þ enhanced the
fraction of monomeric CaBP2 and was therefore present until
the gel filtration for the experiments shown in the manuscript.
Isothermal titration calorimetry (ITC) was performed with a VP-
ITC isothermal titration calorimeter (MicroCal/GE Healthcare,
Munich, Germany) at 20C with 210–250 s of spacing time
between injections for allowing complete temperature equilibra-
tion with the reference cell. CaBP2-wt or CaBP2-p.Phe164* pro-
teins (110–120 mM) were titrated with a buffer solution containing5, 2012
5mMCa2þwith the following parameters: one injectionwith 2 ml,
50 more injections with 5 ml, and a stirring speed of 300 rpm. A
blank titration was performed with the same parameters but
without protein in the sample cell, i.e., Ca2þ-containing buffer
was injected into Ca2þ-free buffer.Analysis of CaBP2 Regulation of Cav1.3 in Transfected
Cells
Human embryonic kidney (HEK) cells transformed with SV40
T-antigen (HEK 293T cells) were maintained in DMEM with 10%
fetal bovine serum (Invitrogen, CA), 50 U/ml penicillin, and
50 mg/ml streptomycin at 37C in a humidified atmosphere with
5% CO2. Cells were grown to ~80% confluence and transfected
with FuGENE 6 (Roche, Basel, Switzerland) according to themanu-
facturer’s protocol. Cells were transfected with cDNAs encoding
rat Cav1.3 a1 subunit (1 mg from D. Lipscombe at Brown Univer-
sity; GenBank accession number AF370010), b2a (0.5 mg; RefSeq
accession number NM_053581), and a2d (0.5 mg; GenBank
M21948), as well as with 0.06, 0.006, or 0.0006 mg WT or
p.Phe164* GFP-CaBP2 or 0.06 mg pEGFP-N1 vector (for Cav1.3
alone). The human WT and MT CaBP2 proteins were cloned
into NheI and BamHI sites of the pEGFP-N1 vector (Clontech,
CA) and verified by DNA sequencing before use.
Whole-cell patch-clamp recordings were performed at room
temperature 36–60 hr after transfection. Extracellular recording
solutions contained 150 mM Tris, 1 mM MgCl2, and 10 mM
CaCl2. Intracellular recording solutions contained 140 mM
N-methyl-d-glucamine, 10 mM HEPES, 2 mM MgCl2, 2 mM Mg-
ATP, and 5 mM EGTA. The pH of extracellular and intracellular
recording solutions was adjusted to 7.3 with methanesulfonic
acid. These conditions, including the use of relatively high
external Ca2þ and internal EGTA, were used for maximizing the
Ca2þ currents and are typical of those used for characterizing
Ca2þ-dependent inactivation of Cav1.3 in transfected HEK 293T
cells.11 Reagents used for electrophysiological recordings were
obtained from Sigma-Aldrich (St. Louis, MO). Electrode resistances
in the recording solutions were typically 2–4 MU. Currents were
recorded with an EPC-10 patch-clamp amplifier driven by Patch-
Master software (HEKA Electronics, Lambrecht/Pfalz, Germany).
Leak and capacitive transients were subtracted according to a P8
protocol. Data were analyzed with routines written in IGOR Pro
software (WaveMetrics, Lake Oswego, OR). Averaged data repre-
sent the means5 the standard error of the mean [SEM]. Statistical
differences between groups were determined by a student’s t test
(inactivation data) or ANOVA (IV data) with Sigma Plot software
(Systat Software, San Jose, CA). Current-voltage curves were fit
with the following function: g(V  E) / [1 þ exp[(V  V1/2) / k] þ
b], where g is the maximum conductance, V is the test potential,
E is the apparent reversal potential, V1/2 is the potential of half
activation, k is the slope factor, and b is the baseline.
For immunoblotting, HEK 293T cells (36 hr after transfection)
were homogenized in 1 ml of ice-cold standard RIPA lysis
buffer containing Complete Mini Protease Inhibitor Cocktail
(Roche) and were solubilized at 4C for 30 min. Insoluble
material was removed by centrifugation at 600 3 g for 5 min,
and the supernatants were used immediately or aliquoted and
stored at 80C. Equal amounts (20 mg) of proteins were re-
solved by SDS-PAGE and were transferred to nitrocellulose.
Immunoblotting was performed with rabbit polyclonal anti-
bodies against CaBP2 (UW92 1:2,000)6,16 and was followed
by HRP-conjugated anti-rabbit antibodies (1:3,000; AmershamThe AmericBiosciences, NJ) and enhanced chemiluminescent detection
reagents (GE Healthcare, WI).Results
Next-Generation Sequencing of the DFNB93 Region
Identifies a Splice-Site Mutation in CABP2
The DFNB93 region contains more than 300 annotated
and hypothetical genes, and several genes are expressed
in the mouse and human inner ear. Because there are
many strong candidate genes in the region,5 we sequenced
all genes and noncoding genes in this region by using
a customDNA capture array to identify the disease-causing
mutation in one affected individual from the family. The
final target region on the array included 1.1Mb for a total
of 449,007 probes, and contained 85% of the original
target area. After sequencing, reads were aligned to the
human genome, and 27.7% of the reads were on target.
Mean coverage in the target area was 97.63.
After the identified homozygous variants were filtered
through the 1000Genomes Project November 2010 release
and dbSNP131, 47 previously unreported variants re-
mained and included two exonic mutations, one splicing
mutation, six nontranslated mutations, 16 intergenic
(downstream or upstream) mutations, and 22 intronic
mutations. The two exonic variants included one nonsy-
nonymous variant, c.1379A>G (p.Glu460Gly) (RefSeq
NM_003626.2 [NP_003617.1]), in PPFIA1 (MIM 611054)
and synonymous variant c.174G>A (p.Pro58Pro) (RefSeq
NM_033036.2 [NP_149025.1]) in GAL3ST3 (MIM
608234). The splice-site variant, c.637þ1G>T (RefSeq
NM_016366.2), was located at the 50 donor site of intron
6 of CABP2 (Figure 1 and Figure S1, available online).
The variants in PPFIA1 and CABP2 were subsequently
validated by Sanger DNA sequencing, which only con-
firmed the splicing variant in CABP2. Both variants were
present in 100% of the reads, although the variant in
PPFIA1 only had 53 coverage compared to the 343
coverage of CABP2—this might explain the lack of confir-
mation of the first variant. Next, we checked the inheri-
tance of the CABP2 variant in the entire Sh10 family
(Figure 1) and screened an additional 100 random Iranian
controls to ensure that the variant is not a frequent poly-
morphism. The mutation was not detected in any of the
controls, and inheritance was consistent with hearing
loss in the family.
Several prediction programs (Human splicing finder
v.2.4.1, NNSPLICE 0.9, and Netgene 2)17–19 indicate that
the c.637þ1G>T mutation in CABP2 causes a loss of the
functional donor site at this position. Loss of the 50 donor
site will most likely result in exon skipping of exon 6 or the
use of cryptic splice sites.CABP2 c.637þ1G>T Leads to Exon Skipping
Because we could not detect CABP2 mRNA expression in
human blood or saliva, we evaluated the effect of thean Journal of Human Genetics 91, 636–645, October 5, 2012 639
Figure 2. CABP2 c.637þ1G>T Leads to
Exon Skipping
(A) A schematic illustration of the CABP2-
pSPL3 exon trap. CABP2 exon 6 and flank-
ing introns (dark gray)— with a WT or MT
(c.637þ1G>T) 50 donor site—were cloned
into the pSPL3 vector (light gray). The
pSPL3 vector contains a portion of the
HIV-1 tat gene, an intron containing the
multiple cloning site, and functional 50
splice donor (50 sD) and 30 splice acceptor
(30 sA) sites.
(B) COS-7 cells were transfected with
WT or MT CABP2 or an empty pSPL3
vector (‘‘E’’). After RNA isolation, splicing
products were analyzed by RT-PCR and
visualized by agarose-gel electrophoresis.
In case of an empty vector (‘‘E’’), only
vector-vector splicing (2) will occur,
leading to a 177 bp secondary product. If
exon 6 contains functional 50 sD and 30 sA sites (WT), both vector-exon splicing (1) and vector-vector splicing (2) will occur and will
lead to 177 bp and 325 bp secondary PCR products, respectively. Mutant plasmids containing the c.637þ1G>T (MT) 50 donor splice-
site mutation only showed vector-vector splicing (2), confirming that this mutation results in exon skipping of exon 6. Secondary
PCR products were confirmed by sequencing. The following abbreviation is used: Bl, blank.c.637þ1G>T CABP2 mutation on splicing by an exon-
trapping system. We cloned exon 6 of CABP2 and the
surrounding introns (with WT and MT c.637þ1G>T
50 donor sites) into the exon-trapping vector pSPL3
(Figure 2A). The multiple cloning site of pSPL3 is located
within the intron of a minigene and is flanked by func-
tional splice donor (sD) and splice acceptor (sA) sites. If
the cloned DNA contains an exon with functional sD
and sA sites, splicing will occur between the vector and
insert sequences. If regular minigene splicing occurs,
a secondary 177 bp PCR product is seen with primers
against the minigene exon sequences. If CABP2 exon 6
splice sites are used, a 325 bp product is amplified; this
was the case with WT cDNA (Figure 2B). Analysis of
cDNA prepared from COS-7 cells transfected with a MT
c.637þ1G>T 50 donor site only revealed a PCR product
of 177 bp, indicating that the mutation at c.637þ1G>T
leads to a complete skipping of exon 6 (Figure 2B). The
correct sequence of all secondary PCR products was con-
firmed by Sanger DNA sequencing. Skipping of exon 6
is expected to lead to a shifted reading frame and a prema-
ture truncation of the protein (p.Phe164Serfs*4 [RefSeq
NP_057450.2]).
CABP2 c.637þ1G>T Is a Founder Mutation
To identify additional individuals with mutations in
CABP2, we screened 39 consanguineous Iranian families
affected by variable degrees of prelingual hearing loss
by genotyping three microsatellite markers (D11S913,
D11S1889, and D11S1337) near CABP2. We identified
two families (Sh11 and He) with affected individuals who
were homozygous in this region (Figure 1). Affected family
members presented with an audiogram similar to the
affected individuals in the Sh10 family (Figure 3). Sanger
DNA sequencing of all seven exons and intron-exon
boundaries of CABP2 revealed the same c.637þ1G>T640 The American Journal of Human Genetics 91, 636–645, Octobermutation in these families. To investigate whether the
c.637þ1G>T splice-site mutation in Iranian families
Sh10, Sh11, and He is a founder mutation, we analyzed
an additional set of microsatellite markers (n ¼ 5) and
SNPs (n ¼ 13) in the region (Figures S2–S4). This showed
that affected individuals from the three families shared
the same haplotype in a region of 0.52 Mb (Figure S5),
which suggests that the mutation found in these three
families arose on the same ancestral haplotype.
Mutations in CABP2 Cause Moderate-to-Severe
Hearing Loss
All affected individuals with the c.637þ1G>T mutation in
CABP2 present with a prelingual, stable, and bilateral form
of hearing loss with a similar audiometric profile. The
hearing loss is moderate to severe and is more pronounced
in the mid frequencies, resulting in a typical U-shaped
audiogram (Figure 3). Average speech-reception thresholds
were 64 db (right) and 64 db (left) for Sh10, 82 db (right)
and 72 db (left) for Sh11, and 75 db (right) and 80 db
(left) for He. ABR recordings showed comparable hearing
thresholds to those of pure-tone audiograms. TEOAEs
were negative in all affected individuals. Routine clinical
examinations did not reveal any special ophthalmological
findings. Upon cardiovascular investigation in the Iranian
families, no sign of bradycardia was noted, although this
had been previously reported for alterations in Cav1.3
(encoded by CACNA1D [MIM 114206]).20 However,
physical characteristics of the affected individuals showed
ectomorphic and Marfanoid features. Because mutations
in CABP4 (MIM 608965) cause night blindness21 and
CABP2 is also expressed in the retina, ophthalmologic
investigations were performed in affected individuals
from the Iranian families, but they did not reveal any eye
disorder except in one patient from family He; this patient
was diagnosed with both myopia and astigmatism.5, 2012
Figure 3. Audiogram
Mean air conduction (AC) thresholds of the left ear for each
family. Hearing loss is symmetric.
Figure 4. Isothermal Titration Calorimetry ofWT and Truncated
CaBP2
(A) Trace of the calorimetric titration of 5 ml aliquots (after one
initial injection of 2 ml) of 5 mM CaCl2 into 1.3 ml of 110 mM re-
combinant WT apo-CaBP2. A robust endothermic binding reac-
tion was observed.
(B) Trace of the calorimetric titration of 5 ml aliquots (after one
initial injection of 2 ml) of 5 mM CaCl2 into 1.3 ml of 114 mM re-
combinant truncated apo-CaBP2 (MT CaBP2 [DEF hands 3 and 4]).
In contrast to the WT apo-CaBP2, the truncated protein leads to
a weaker and exothermic reaction.
(C) Trace of the blank titration curve for both experiments A and B
with the same parameters but without protein in the sample cell.Effects of Exon Skipping Due to CABP2 c.637þ1G>T
on Ca2þ Binding of CaBP2
The frame shift and premature stop are expected to trun-
cate CaBP2 such that it lacks the Ca2þ binding EF hands
3 and 4. Because the remaining portion of the MT protein
would possess only one functional EF hand, we hypothe-
sized that the truncation should alter Ca2þ binding. To
test this hypothesis, we performed ITC by using His6-
tagged WT and p.Phe164* (a premature stop predicted to
result from exon skipping) CaBP2 purified from E. coli.
Both proteins were readily purified and remained soluble
in the absence and presence of Ca2þ (Figure S6). Ca2þ
favored the monomeric form and, hence, was only
removed prior to the ITC in the experiments shown. By
ITC, we found an endothermic Ca2þ-binding reaction
(probably mediated by EF hands 1, 3, and 4; Figure 4A)
for WT CaBP2 in three independent experiments. In con-
trast, the truncated protein displayed a weaker exothermic
reaction (probably mediated by EF hand 1, Figure 4B) in
three independent experiments. These results confirm
that the truncation predicted to arise from the c.637þ
1G>T mutation via exon skipping alters Ca2þ binding
and thereby might interfere with its role as a Ca2þ sensor.
Effects of Exon Skipping Due to CABP2 c.637þ1G>T
on Cav1.3 Ca
2þ Currents
To gain further insights into the functional consequences
of the c.637þ1G>T mutation, we compared the abilities
of the WT and truncated CaBP2 to modulate Cav1.3 Ca
2þ
channels. These channels mediate presynaptic Ca2þ influx
and subsequent exocytosis of glutamate in auditory inner
hair cells (IHCs).22,23 CaBP2 is also localized in IHCs11
and so might play a role in regulating Cav1.3 and IHC
synaptic transmission. In transfected HEK 293T cells,
CaBP family members, including CaBP1 (encoded by
CABP1 [MIM 605563]) and CaBP4, strongly suppress CDI
of Cav1.3.
11,12 CDI is a negative feedback regulation of
Cav channels and is mediated by incoming Ca
2þ ions
and calmodulin binding to the pore-forming Cav a1
subunit.8 CaBPs inhibit Cav1.3 CDI in part by competing
with calmodulin for binding to the channel.11 Thus, weThe Americcompared the effects ofWTandMT CaBP2 on the inactiva-
tion of Cav1.3 Ca
2þ currents in transfected HEK 293T cells.
In initial immunoblot experiments to confirm the pro-
tein levels of WT and MT CaBP2, we noticed that the MT
CaBP2 exhibited ~10-fold higher protein levels than did
the WT CaBP2 (Figure 5A). To account for this difference,
we compared CDI in cells expressingWTorMTCaBP2 afteran Journal of Human Genetics 91, 636–645, October 5, 2012 641
Figure 5. c.637þ1G>T Mutation Impairs
CaBP2 Regulation of Cav1.3 Ca
2þ Chan-
nels
(A) The MT CaBP2 shows greater protein
levels in transfected HEK 293T cells.
Lysates of cells cotransfected with Cav1.3
subunits and WT or MT CaBP2 were sub-
ject to immunoblotting with CaBP2 anti-
bodies (top panel). WT and MT CaBP2
were cotransfected at different molar ratios
as indicated. The lower panel was probed
with b-actin antibodies for confirming
equal loading between groups.
(B) TheMTCaBP2 showsweaker regulation
of CDI. HEK 293T cells were cotransfected
as in (A). Ca2þ currents were evoked by
0.5 s pulses from90mV to10mV. Inac-
tivation was measured as r500, which was
the current amplitude at the end of the
pulsenormalized to thepeakcurrent ampli-
tude. So that different protein levels (also
in C) could be accounted for, comparisons
to WT were made with cells transfected
with cDNA encoding MT CaBP2 at levels
ten times lower than those of WT CaBP2.
Parentheses indicate numbers of cells.
*p < 0.05. Error bars represent the SEM.
(C and D) The MT CaBP2 shows a weaker
ability to suppress Cav1.3 current density
than does the WT CaBP2. Ca2þ currents
were evoked by 50 ms pulses to variable
voltages from 90 mV. Current amplitude
was normalized to cell capacitance and
plotted against test voltage. Error bars
represent the SEM.transfection with 10-fold more cDNA for WT CaBP2 than
for MT CaBP2. Ca2þ currents were evoked by 500 ms step
depolarizations, and CDI strength was measured as the
fraction of residual current at the end of the pulse relative
to the peak current amplitude (r500). CDI was significantly
weaker in cells transfected with maximal levels of WT
CaBP2 (r500 ¼ 0.925 0.01, n ¼ 6; p < 0.001) than in cells
transfected with Cav1.3 alone (r500 ¼ 0.195 0.02, n ¼ 7)
(Figure 5B). At protein levels comparable to those of the
WT CaBP2 at maximal transfection, theMT CaBP2 showed
weaker CDI suppression than did the WT (r500 ¼ 0.62 5
0.06, n ¼ 9; p < 0.02). At this protein level, the MT
CaBP2 was still effective in suppressing CDI because r500
was significantly greater than for Cav1.3 alone (p ¼
0.001). This difference in WT and MT CaBP2 was negated
at lower protein levels of both (r500 ¼ 0.32 5 0.11 and
n ¼ 6 for WT versus r500 ¼ 0.36 5 0.03 and n ¼ 6 for
MT CaBP2; p ¼ 0.09).
In HEK 293T cells, CaBPs also have a second effect of
inhibiting Cav1.3 current density. WT CaBP2 also sig-
nificantly inhibited Cav1.3 current density (maximally
~78%; p < 0.001; Figure 5C). By contrast, the MT CaBP2
had no effect on Cav1.3 current density (p ¼ 0.35 com-
pared to Cav1.3 alone). Taken together, these results
show that c.637þ1G>T impairs the function of CaBP2
regulating Cav1.3 channels and potentially other targets
important for hearing.642 The American Journal of Human Genetics 91, 636–645, OctoberEvaluation of CABP2 Mutations in Affected
Individuals with Other Ethnicities and Individuals
with Usher Syndrome
We screened 24 unrelated affected Belgian and Dutch
individuals with a moderate-to-severe hearing loss for
mutations in CABP2 by sequence analysis of the exons
and exon-intron boundaries, but we could not identify
a clear damaging mutation in any of them. In addition,
given that CaBP2 is localized in both the retina and inner
ear, we considered it as a candidate gene in which
mutations could cause Usher syndrome. We performed
genotype analysis for three flanking microsatellite
markers—D11S1883, D11S1889, and D11S4113—in 14
small Usher-syndrome-affected families with one to three
affected individuals per family. For one USH1-affected
family and one USH2-affected family, genotypes were
compatible with linkage. However, sequence analysis of
exons and exon-intron boundaries did not reveal any puta-
tively pathogenic sequence variant.Discussion
Like other CaBP family members, CABP2 is closely related
to calmodulin. Different from calmodulin, CaBP2 has
only three functional Ca2þ-binding EF-hand domains (EF
hands 1, 3, and 4) because EF hand 2 contains a 3 amino5, 2012
acid deletion that would inhibit Ca2þ binding.6 Although
calmodulin is localized in nearly all eukaryotic cells,
CaBP2 has thus far been detected in the retina6 and
the inner ear.11 In this study, we identified CABP2 muta-
tions in affected individuals who are from the DFNB93-
affected family and who present with moderate-to-severe
hearing loss.
We identified three Iranian families (Sh10, Sh11, andHe)
affected by a splice-site CABP2 mutation, c.637þ1G>T,
that segregates with hearing loss (Figure 1 and Figure S1).
To evaluate the effect of the splice-site mutation on
splicing, we developed an exon-trapping system (Figure 2).
This indicated that the c.637þ1G>T mutation most likely
leads to skipping of exon 6. Skipping of exon 6, if RNA is
not degraded by nonsense-mediated mRNA decay, is
predicted to lead to a shifted reading frame, a premature
truncation of the protein (p.Phe164Serfs*4), and a com-
plete loss of EF hands 3 and 4. To check whether the
c.637þ1G>T mutation in three Iranian families arose on
the same ancestral haplotype, we genotyped several micro-
satellite markers and SNPs near CABP2 (Figure S5). We
found that affected individuals from the three families
shared a haplotype of 0.52 Mb, suggesting that the c.637þ
1G>T mutation is a founder mutation inherited from an
ancient common ancestor. The small size of the shared
region suggests that this mutation might be hundreds or
even thousands of years old.
Structural analyses of Ca2þ binding to CaBP1, which, like
CaBP2, has a nonfunctional EF hand 2, indicate that high-
affinity Ca2þ binding to EF hands 3 and 4 induces con-
formational protein changes that might be required for
Ca2þ-dependent regulation of effectors. In contrast, Ca2þ
binds with relatively low affinity to EF hand 1.24 Indeed,
the CaBP2 truncation predicted by c.637þ1G>T altered
Ca2þ binding in our ITC experiments (Figure 4), which is
consistent with the expectation that EF hands 3 and 4 are
required for high-affinity Ca2þ binding in WT CaBP2.
We showed previously that although CaBP1, CaBP2,
CaBP4, and CaBP5 are present in mouse IHCs, CaBP1
most strongly suppressed CDI of Cav1.3 channels.
11 Using
higher levels of CaBP2 cDNA than in our previous study,
we now report that CaBP2, like CaBP1, can nearly abolish
CDI. It is important to note that factors governing the
protein levels and localization of CaBPs in IHCs might
differ from those in transfected HEK 293T cells. For
example, IHCs might possess sorting and traffickingmech-
anisms that favor the abundance of CaBP2 at presynaptic
Cav1.3 channel clusters, such that CaBP2, indeed, could
play an important role in modulating IHC Ca2þ influx.
Our electrophysiological results show that the trunca-
tion due to the c.637þ1G>T mutation impairs but does
not abolish the ability of CaBP2 to modulate Cav1.3. By
analogy with CaBP1/Cav1.2 interactions,
25 the CaBP2
C-terminal, which is absent in the truncated mutant,
might be necessary for anchoring CaBP2 to Cav1.3
and permitting efficient competition with calmodulin.
However, the major determinants of CaBP1 regulationThe Americof Cav1 channels are the N-terminal lobe and linker
region.25 The corresponding regions are spared in the trun-
catedMT CaBP2, which likely permits residual modulation
of Cav1.3 CDI.
The observed reduction of Cav1.3 current density by
CaBP2 is consistent with the effects of CaBP1 and CaBP4
on Cav1.3 channels in transfected HEK 293T cells.
11,12
CaBPs can inhibit Cav1 channel current density by antag-
onizing the acceleration of forward trafficking of Cav1
channels by calmodulin.26,27 The CaBP2 truncation was
more potent in preventing this effect on current density
than in impairing the inhibition of CDI (Figure 5C). This
suggests that the CaBP2 C-terminal lobe, which is absent
in the c.637þ1G>T mutant, might be more important in
regulating plasmamembrane levels of Cav1.3 than in regu-
lating CDI.
On the basis of our present findings and the colocaliza-
tion of CaBP2 and Cav1.3 in IHCs,
11 dysregulation of
IHC synaptic transmission could be one pathogenic mech-
anism underlying hearing impairment in DFNB93. Cav1.3
channels are the primary voltage-gated Ca2þ channels in
IHCs and outer hair cells and are required for hearing in
mice and humans.20,22,23 In IHCs, the c.637þ1G>T muta-
tion in CABP2 would most likely enhance inactivation of
synaptic Ca2þ influx. This, in turn, could reduce rates
of transmitter release and consequently diminish spiral
ganglion neuron firing and ascending auditory-pathway
activation. If, like in HEK 293T cells, CaBP2 normally
reduces Cav1.3 current density in IHCs, the c.637þ1G>T
mutation in CABP2 could also have deleterious effects via
comparatively higher Cav1.3 current density. Excessive
Ca2þ entry and the ensuing increased glutamate release
could ultimately be toxic and lead to degeneration of
hair cells, afferent synapses, and spiral ganglion neurons.
The presence of CaBPs other than CaBP2 in IHCs could
partially compensate for the effects of the c.637þ1G>T
mutation in CABP2, which might explain the moderate
hearing loss associated with DFNB93.
It is noteworthy that the structural CaBP2 defect caused
by the c.637þ1G>T mutation in DFNB93 is analogous to
that in CaBP4 of individuals who have congenital cone-
rod synaptic disorder and who carry a CABP4 mutation
(c.646C>T [p.Arg216*]).28 Individuals with a c.646C>T
(p.Arg216*) mutation exhibit reduced visual acuity and
abnormal color vision, which could result from disruption
of CaBP4 interactions with Cav1.4 Ca
2þ channels.28 Like
Cav1.3 in IHCs and hearing, Cav1.4 in photoreceptors
regulates glutamate release and is required for vision.29,30
Moreover, CaBP4 is localized in photoreceptor presynaptic
terminals and enhances Cav1.4 function, although via a
different mechanism than CaBP2 regulation of Cav1.3.
16
In affected individuals with the c.646C>T (p.Arg216*)
mutation, mRNA encoding the truncated CaBP4 is not
subject to nonsense-mediated decay and is still detected
at levels comparable to those of the mRNA encoding WT
CaBP4.28 If the same is true for the c.637þ1G>T mutation
in CABP2, our electrophysiological results most likelyan Journal of Human Genetics 91, 636–645, October 5, 2012 643
pinpoint one disease mechanism in DFNB93-affected
individuals. The fact that similar alterations in the Cav1
regulators, CaBP2 and CaBP4, lead to analogous defects
in hearing and vision, respectively, supports the physio-
logical significance of CaBP-Cav1 interactions for sensory
transmission.
However, CaBP2 might be required for normal hearing
through roles in other cell types besides IHCs. CaBP1 and
CaBP5 are localized in multiple neuronal cell types in the
retina and likewise,6 CaBP2 could be localized in spiral
ganglion neurons, as well as in hair cells. Moreover,
CaBP2 could also interact with targets in addition to
Cav1.3.
31–33
In conclusion, we identified mutations in CABP2 in
individuals with moderate-to-severe hearing loss. Muta-
tions in CABP2 cause an audiometric phenotype that is
similar to those related to TECTA mutations but differs
from the typical profound deafness phenotype that is
seen in most families segregating arNSHL. Our results sug-
gest the importance of screening for mutations in CABP2,
as well as in TECTA, in families with this milder audio-
metric phenotype.Supplemental Data
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